Neoadjuvant Dabrafenib Plus Trametinib Has High Pathological Response Rates in Clinical Stage III Melanoma, But Low Rates of Recurrence-Free Survival
Updated analysis of the phase II NeoCombi study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Updated analysis of the phase II NeoCombi study
New indication concerns adjuvant treatment for ALK-positive NSCLC at high risk of recurrence
Findings from the CheckMate 77T study
Findings from the exploratory biomarker analyses of the DESTINY-Gastric01 study
It is indicated in combination with cisplatin and gemcitabine
Findings from the FIGHT-207 basket study
Primary results from the DESTINY-PanTumor01 study
Approval is based on pharmacokinetic, dosimetry, and safety data from NETTER-P study in adolescent patients and also on the extrapolation of efficacy outcomes observed in NETTER-1 study which supported the original approval in adult patients
Findings from the TRIANGLE study
It is intended for the treatment of patients with previously treated metastatic colorectal cancer
Findings from the NEOpredict-Lung study
The innovaTV 301 study results fulfill the post-marketing requirement of the previous accelerated approval
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.